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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to review guidelines in current use and under
development to determine similarities, emerging trends
and the implications for the use and development of
guidelines in the future.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to develop an understanding of the guidelines pro-
cess and the means of establishing appropriate study de-
sign criteria to apply in international pharmacoeconomic
studies in order to meet the requirements of as many
guidelines as possible.
Guidelines for the economic evaluation of pharmaceuticals
are being developed around the world by academia, indus-
try, government, payers and external consultants. These
guidelines can be categorized according to their main pur-
pose: methods guidelines; guidelines for formulary submis-
sions; principles of conduct; and substantiation of evidence
for promotional claims. Review of the guidelines reveals a
number of common themes which will allow some com-
parison of studies across countries. Differences outside
these common themes may be attributable to particular
differences in the settings in which individual guidelines
are applicable. However, what is most noticeable is the
trends emerging from what appears to be a flourishing
field of guidelines development. Methodological trends are
evident in study design (with greater acceptance of model-
ling studies), valuation of health outcomes and productiv-
ity changes (indirect costs). In addition, the formal require-
ment for economic evaluation of pharmaceuticals is being
extended into more countries and we can expect to see
pharmacoeconomic guidelines being increasingly used. If
this encourages cost-effective prescribing then the ultimate
impact will be in providing benefit to patients.
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WORKSHOP OBJECTIVE: The objective of this work-
shop is to update participants on the progress of the
SCRIPT project.
PARTICIPANTS WHO WOULD BENEFIT: Stakehold-
ers in medication use quality would benefit by participat-
ing in this workshop.
Background for the SCRIPT project was presented at last
year’s meeting of ISPOR in Philadelphia. Since that time,
there has been significant progress. The SCRIPT project is
the first concerted effort of the Coalition for Quality in
Medication Use. The purpose of the project is to create a
method for consensus-based quality indicator development
and a compendium of core indicators measuring quality in
medication use that will be recommended for implementa-
tion by coalition members. The Coalition for Quality in
Medication Use currently includes about 50 national orga-
nizations. The SCRIPT project is funded by HCFA, and
staffed by JCAHO. Daily management is provided by a
Steering Committee composed of representatives from
AAHP, AHCPR, AHQA, AMA, APhA, HCFA, JCAHO,
NCQA, and two science advisors. The coalition met for the
first time in July 1998. A Call for Measures has gone out
and existing compendia of measures have been collected.
Criteria for evaluating measures are in development and a
technical expert panel is being formed to evaluate the mea-
sures in a cluster of clinical conditions with high disease
burden and significant quality issues in medication use.
Clinical conditions, medication use issues, and some of the
considered measures will be identified at this workshop. Ad-
ditional progress in this area will be shared in the workshop
as well as preliminary plans to test candidate measures.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to demonstrate the nature of decision-making
tools employed within the managed care industry to evalu-
ate pharmacy-related issues. This workshop will use an
economic model to demonstrate the type of logic used by
MCOs to project pharmacy costs and to evaluate the im-
pact of formulary changes. Participants will learn how to
utilize pharmacy and medical administrative claims data
to assess the potential increase in pharmacy costs associ-
ated with the introduction of new drugs and/or treatments.
PARTICIPANTS WHO WOULD BENEFIT: Managed
care decision-makers, pharmacy directors, and health econ-
omists who are involved in the evaluation of pharmacy
costs and business issues related to formulary changes.
Rising pharmaceutical expenditures in recent years have
led to increased scrutiny of this benefit among healthcare
insurers in the United States. Managed care organizations
(MCOs) are increasingly questioning available options with
regard to the introduction of new classes of prescription
drugs and other new therapies. Economic models are an im-
portant vehicle that may be utilized by decision-makers to
better understand the financial implications of formulary
changes. We will discuss a model recently developed to
simulate the impact of prescription Cox-2 inhibitor medi-
cations on pharmacy costs of a managed care health plan.
This session will explain the assumptions made, data used,
and processes employed in the development of this eco-
nomic model.
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